Researchers identify critical window for boosting immunotherapy response in prostate cancer
Researchers at Roswell Park Comprehensive Cancer Center have shown that hormone-blocking therapies commonly used to treat prostate cancers temporarily activate the body's immune response before those immune effects begin to fade over time. In a new publication in the Journal for Immunotherapy of Cancer, a team led by Kent Nastiuk, Ph.D., reports this discovery—and points the way to a treatment…
We haven't written up this one. Medical Xpress has the full story — the link below goes straight to it.
